SecBot SecBot
PRESS-RELEASE ·Filed Jul 22, 2026

CHRS

Coherus Oncology, Inc.
NEUTRAL
Impact 1/10
Horizondays Processed3mo ago WireGlobeNewswire
Press release · Earnings

Drugs in focus

CHRS drug pipeline →

LOQTORZI

● Neutral Named in this press release
Impact
Phase
Approved
Time to market
Already approved and commercially available in the U.S. since October 2023.
Next catalyst
None dated

What to watchLOQTORZI is a commercial-stage asset generating growing but still modest revenue (Q2 2026 net sales of $13.6M, up 15% sequentially). The company reported Q3 2026 results on November 9, 2026 with a $39.3M net loss and announced a strategic prioritization plan focusing on tagmokitug/toripalimab for esophageal cancer. Watch for Q3 LOQTORZI revenue trajectory and any updates on the expedited esophageal cancer development path. The stock trades near $0.84, down from a 52-week high of $2.62, reflecting the company's cash burn and pipeline-stage focus beyond LOQTORZI.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.43
T+0 close · Jul 22, 2026 · via day close
Latest settled
−25.17%
T+60 · $1.07
Vs SPY
−28.44%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 22 $1.43entry
  2. T+1 · 4mo ago 0.00%α +1.23% · $1.43
  3. T+5 · 4mo ago −1.40%α +1.00% · $1.41
  4. T+20 · 3mo ago −6.99%α −9.89% · $1.33
  5. T+60 · 5w ago −25.17%α −28.44% · $1.07
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Coherus Oncology, Inc. announced it will report its Q2 2026 results on August 5, 2026.

Key Facts

  • Coherus Oncology, Inc. announced it will report its Q2 2026 results on August 5, 2026.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
85% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3331650

Track record

15 reports on CHRS

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +16.97% at T+5 after the Feb 28, 2026 report. 2 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today Institutional Cluster Bearish 4/10 Entry $0.5250 Now $0.5060 +3.62% settles Feb 12
  2. Nov 9, 20267d ago Press Release Neutral 5/10 Entry $0.6409 Now $0.5060 −21.05% settles Feb 8
  3. Oct 29, 202618d ago 8-K Bullish 6/10 Entry $0.8984 Now $0.5060 −43.68% settles Jan 27
  4. Oct 14, 20264w ago Press Release Neutral 4/10 Entry $1.07 Now $0.5060 −52.71% settles Jan 12
  5. Aug 17, 202613w ago Press Release Neutral 4/10 Entry $1.34 to $0.6409 Now $0.5060 −62.24% ▼ −52.17% −50.13% vs SPY
  6. Jul 22, 202616w ago Press Release Neutral 1/10 Viewing Entry $1.43 to $1.07 Now $0.5060 −64.62% ▼ −25.17% −28.44% vs SPY
  7. Jun 15, 202622w ago 8-K Neutral 3/10 Entry $1.38 to $1.34 Now $0.5060 −63.33% ▼ −2.90% −3.90% vs SPY
  8. Jun 12, 202622w ago Institutional Cluster Bearish 4/10 Entry $1.40 to $1.37 Now $0.5060 +63.86% ▲ +2.14% +5.41% vs SPY
  9. May 28, 202624w ago DEFA14A Neutral 4/10 Entry $1.65 to $1.42 Now $0.5060 −69.33% ▼ −13.94% −15.67% vs SPY
  10. May 11, 202627w ago Press Release Mixed 6/10 Entry $1.71 to $1.27 Now $0.5060 −70.41% ▼ −26.02% −30.41% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 27m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 22, 2026